2α-methyl-19-nor-1α-hydroxy-homopregnacalciferol and its uses
US8399438B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 18, 2005 |
| Grant date | Mar 19, 2013 |
| Priority date | — |
| Expiry date | Apr 5, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention discloses 2α-methyl-19-nor-vitamin D analogs, and specifically 2α-methyl-19-nor-1α-hydroxy-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.